Viatris (VTRS) Total Debt (2019 - 2026)
Viatris' (VTRS) quarterly Total Debt came in at $14.3 billion in Q1 2026, down 9.53% year-on-year from $15.9 billion in Q1 2025, and down 0.51% quarter-over-quarter from $14.4 billion in Q4 2025.
Viatris (VTRS) Total Debt (2019 - 2026) Analysis & Trends
Viatris' Total Debt history runs 8 years deep, the most recent figure standing at $14.3 billion for Q1 2026.
- On a quarterly basis, Total Debt fell 9.53% year-over-year to $14.3 billion in Q1 2026; TTM through Mar 2026 was $14.3 billion, a 9.53% decrease from a year earlier, with the FY2025 full-year figure at $14.4 billion, up 2.67% from the prior year.
- Total Debt retreated to $14.3 billion in Q1 2026 per VTRS's latest filing, from $14.4 billion in the prior quarter.
- Across five years, Total Debt topped out at $20.0 billion in Q2 2022 and bottomed at $14.0 billion in Q4 2024.
- The 5-year median for Total Debt is $17.1 billion (2023), against an average of $16.9 billion.
- Across the five-year window, Total Debt slipped 22.53% in 2024 and gained 2.67% in 2025, its largest moves.
- Year by year, Total Debt stood at $19.3 billion in 2022, then declined by 5.97% to $18.1 billion in 2023, then declined by 22.53% to $14.0 billion in 2024, then grew by 2.67% to $14.4 billion in 2025, then declined by 0.51% to $14.3 billion in 2026.
- Per Business Quant, the three latest VTRS Total Debt figures stand at $14.3 billion (Q1 2026), $14.4 billion (Q4 2025), and $14.4 billion (Q3 2025).
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Total Debt (Qtr) |
|---|---|---|---|---|---|
| 1 | Haleon | 87.22 Bn | 85.35 Bn | - | 11.45 Bn |
| 2 | Teva Pharmaceutical Industries | 39.60 Bn | 35.87 Bn | 1.97 Bn | 16.63 Bn |
| 3 | Zoetis | 31.46 Bn | 29.52 Bn | 1.62 Bn | 9.05 Bn |
| 4 | Takeda Pharmaceutical | 26.49 Bn | 22.44 Bn | 4.39 Bn | 28.76 Bn |
| 5 | United Therapeutics | 23.03 Bn | 20.88 Bn | 648.10 Mn | - |
| 6 | Universe Pharmaceuticals | 23.03 Bn | -10.56 Bn | - | 7.15 Bn |
| 7 | Viatris | 20.90 Bn | 19.09 Bn | 1.16 Bn | 14.34 Bn |
| 8 | Neurocrine Biosciences | 17.50 Bn | 16.19 Bn | 800.70 Mn | - |
| 9 | Elanco Animal Health | 12.33 Bn | 11.91 Bn | 785.00 Mn | 3.81 Bn |
| 10 | Vireo Growth | 10.57 Bn | 10.41 Bn | 59.30 Mn | 198.60 Mn |
Historic Data
Download Data| Date | Value |
|---|---|
| Mar 31, 2026 | 14.34 Bn |
| Dec 31, 2025 | 14.41 Bn |
| Sep 30, 2025 | 14.44 Bn |
| Jun 30, 2025 | 14.47 Bn |
| Mar 31, 2025 | 15.85 Bn |
| Dec 31, 2024 | 14.04 Bn |
| Sep 30, 2024 | 15.98 Bn |
| Jun 30, 2024 | 16.40 Bn |
| Mar 31, 2024 | 17.97 Bn |
| Dec 31, 2023 | 18.12 Bn |
| Sep 30, 2023 | 17.08 Bn |
| Jun 30, 2023 | 17.27 Bn |
| Mar 31, 2023 | 18.27 Bn |
| Dec 31, 2022 | 19.27 Bn |
| Sep 30, 2022 | 19.48 Bn |
| Jun 30, 2022 | 19.97 Bn |
| Mar 31, 2022 | 19.42 Bn |
| Dec 31, 2021 | 21.58 Bn |
| Sep 30, 2021 | 21.74 Bn |
| Jun 30, 2021 | 22.22 Bn |